Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
Japan
· Delayed Price · Currency is JPY 296.00
+6.00 (2.07%)
Mar 10, 2026, 2:33 PM JST
Taiko Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 4,256 | 4,532 | 5,484 | 3,105 | 5,796 | Upgrade
|
| Short-Term Investments | - | - | - | 400 | 302 | Upgrade
|
| Cash & Short-Term Investments | 4,256 | 4,532 | 5,484 | 3,505 | 6,098 | Upgrade
|
| Cash Growth | -6.09% | -17.36% | 56.46% | -42.52% | 23.34% | Upgrade
|
| Accounts Receivable | 2,449 | 2,428 | 1,985 | 1,798 | 4,056 | Upgrade
|
| Other Receivables | 1 | - | - | - | - | Upgrade
|
| Receivables | 2,450 | 2,428 | 1,985 | 1,798 | 4,056 | Upgrade
|
| Inventory | 1,618 | 1,675 | 1,373 | 1,952 | 3,205 | Upgrade
|
| Other Current Assets | 109 | 126 | 267 | 301 | 424 | Upgrade
|
| Total Current Assets | 8,433 | 8,761 | 9,109 | 7,556 | 13,783 | Upgrade
|
| Property, Plant & Equipment | 3,312 | 3,271 | 3,581 | 6,397 | 7,113 | Upgrade
|
| Long-Term Investments | 268 | 747 | 526 | 867 | 1,338 | Upgrade
|
| Other Intangible Assets | 34 | 27 | 1 | 222 | 299 | Upgrade
|
| Long-Term Deferred Tax Assets | 221 | 105 | 1 | 2 | - | Upgrade
|
| Other Long-Term Assets | 2 | 3 | 2 | 2 | 2 | Upgrade
|
| Total Assets | 12,270 | 12,914 | 13,220 | 15,046 | 22,535 | Upgrade
|
| Accounts Payable | 936 | 338 | 375 | 274 | 309 | Upgrade
|
| Accrued Expenses | 247 | 176 | 75 | 23 | 149 | Upgrade
|
| Current Portion of Long-Term Debt | 792 | 1,206 | 1,206 | 1,039 | 923 | Upgrade
|
| Current Portion of Leases | 14 | 18 | 27 | 29 | 36 | Upgrade
|
| Current Income Taxes Payable | 15 | 728 | 782 | 571 | 1,282 | Upgrade
|
| Other Current Liabilities | 505 | 389 | 581 | 857 | 1,621 | Upgrade
|
| Total Current Liabilities | 2,509 | 2,855 | 3,046 | 2,793 | 4,320 | Upgrade
|
| Long-Term Debt | - | 792 | 1,999 | 2,720 | 3,760 | Upgrade
|
| Long-Term Leases | 10 | 11 | 22 | 21 | 54 | Upgrade
|
| Pension & Post-Retirement Benefits | 623 | 655 | 624 | 659 | 805 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 6 | 20 | 188 | 125 | 104 | Upgrade
|
| Other Long-Term Liabilities | 604 | 618 | 603 | 685 | 686 | Upgrade
|
| Total Liabilities | 3,752 | 4,951 | 6,482 | 7,003 | 9,729 | Upgrade
|
| Common Stock | 10 | 10 | 2,267 | 1,201 | 1,201 | Upgrade
|
| Additional Paid-In Capital | 4,978 | 4,997 | 2,689 | 1,642 | 1,648 | Upgrade
|
| Retained Earnings | 3,450 | 2,526 | 1,628 | 5,239 | 10,134 | Upgrade
|
| Treasury Stock | -237 | -273 | -300 | -348 | -388 | Upgrade
|
| Comprehensive Income & Other | 317 | 703 | 454 | 309 | 211 | Upgrade
|
| Shareholders' Equity | 8,518 | 7,963 | 6,738 | 8,043 | 12,806 | Upgrade
|
| Total Liabilities & Equity | 12,270 | 12,914 | 13,220 | 15,046 | 22,535 | Upgrade
|
| Total Debt | 816 | 2,027 | 3,254 | 3,809 | 4,773 | Upgrade
|
| Net Cash (Debt) | 3,440 | 2,505 | 2,230 | -304 | 1,325 | Upgrade
|
| Net Cash Growth | 37.33% | 12.33% | - | - | -72.68% | Upgrade
|
| Net Cash Per Share | 68.48 | 49.92 | 47.09 | -6.97 | 30.45 | Upgrade
|
| Filing Date Shares Outstanding | 50.25 | 50.19 | 50.15 | 43.58 | 43.58 | Upgrade
|
| Total Common Shares Outstanding | 50.25 | 50.19 | 49.95 | 43.58 | 43.58 | Upgrade
|
| Working Capital | 5,924 | 5,906 | 6,063 | 4,763 | 9,463 | Upgrade
|
| Book Value Per Share | 169.51 | 158.65 | 134.90 | 184.57 | 293.84 | Upgrade
|
| Tangible Book Value | 8,484 | 7,936 | 6,737 | 7,821 | 12,507 | Upgrade
|
| Tangible Book Value Per Share | 168.83 | 158.11 | 134.88 | 179.48 | 286.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.